Institution Directory

Clinical trials at Cedars-Sinai Medical Center

Sites in Los Angeles, CA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 4:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

659

Shown on this page

Current sort

Live official records

Conditions: Mitral Regurgitation, Mitral Valve Insufficiency
Interventions: SAPIEN M3 valve and dock; Device
Lead sponsor: Edwards Lifesciences; Industry
Eligibility: 18 Years and older
Enrollment: 786 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2031
U.S. locations: 44
States / cities: Huntsville, Alabama • Phoenix, Arizona • La Jolla, California + 36 more

Conditions: Refractory Solid Tumors, Relapsed Solid Tumors, Relapsed Neuroblastoma, Refractory Neuroblastoma, Relapsed Rhabdomyosarcoma, Refractory Rhabdomyosarcoma
Interventions: PEEL-224, Vincristine, Temozolomide (TMZ); Drug
Lead sponsor: Theodore Laetsch; Other
Eligibility: 1 Year to 30 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 7
States / cities: Los Angeles, California • San Francisco, California • Boston, Massachusetts + 3 more

Conditions: Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8
Interventions: Atezolizumab, Biospecimen Collection, Computed Tomography, Fludeoxyglucose F-18, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy; Drug · Procedure · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 417 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 391
States / cities: Anchorage, Alaska • Jonesboro, Arkansas • Little Rock, Arkansas + 291 more

Conditions: Anaplastic Astrocytoma, Glioblastoma, Malignant Glioma
Interventions: Radiation Therapy, Temozolomide, Veliparib; Radiation · Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: 3 Years to 25 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 145
States / cities: Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 111 more

Conditions: Peripheral Nerve Injury Upper Limb, Peripheral Nerve Injury (PNI)
Interventions: NTX-001 (PEG-Fusion); Combination Product
Lead sponsor: Neuraptive Therapeutics Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 25
States / cities: Los Angeles, California • San Francisco, California • Orlando, Florida + 20 more

Conditions: Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
Interventions: rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, Rituximab and Lenalidomide, rituximab and bendamustine, rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin, gemcitabine and oxaliplatin, Epcoritamab, rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisone, Lenalidomide, rituximab, ifosfamide, carboplatin, and etoposide phosphate; Drug · Biological
Lead sponsor: Genmab; Industry
Eligibility: 18 Years and older
Enrollment: 543 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 11
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 6 more

Conditions: Pulmonary Valve Insufficiency, Complex Congenital Heart Defect, Tetralogy of Fallot, Pulmonary Regurgitation, RVOT Anomaly
Interventions: Edwards Alterra Adaptive Prestent with SAPIEN 3 Transcatheter Pulmonary Valve System; Device
Lead sponsor: Edwards Lifesciences; Industry
Eligibility: Not listed
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2035
U.S. locations: 23
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 18 more

Conditions: Antihypertensive Agents, High Blood Pressure, Hypertension
Interventions: Telemedicine Barbershop BP Reduction; Other
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 35 Years to 79 Years · Male only
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Symptomatic Genetic Dilated Cardiomyopathy
Interventions: danicamtiv, Placebo; Drug
Lead sponsor: Kardigan, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 332 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 28
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 22 more

Conditions: Heart Failure - NYHA II - IV
Interventions: CRT-D with a Quadripolar LV lead, CRT-D with INGEVITY+ pace/sense lead; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 850 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 42
States / cities: Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 36 more

Conditions: Device Related Thrombosis, Peri-device Leak
Interventions: Transesophageal echocardiography (TEE), Cardiac CTA; Procedure
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 5
States / cities: Los Angeles, California • Roslyn, New York • Charlotte, North Carolina + 2 more

Conditions: PIK3CA Mutation, HER2- Negative Breast Cancer, Hormone Receptor Positive Tumor, Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer
Interventions: Zovegalisib, Capivasertib, Fulvestrant; Drug
Lead sponsor: Relay Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 540 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 52
States / cities: Gilbert, Arizona • Beverly Hills, California • Duarte, California + 42 more

About this Cedars-Sinai Medical Center institution page

What this page lists: ClinicalTrials.gov records that list Cedars-Sinai Medical Center in Los Angeles, CA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Cedars-Sinai Medical Center

Filter and sort this campus

Live official records

The ENCIRCLE Trial

PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors

Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer

Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations

This Study Will Evaluate the Effectiveness of NTX-001, a Surgical Nerve Repair Product When Used in People With Upper Extremity Nerve Lacerations.

Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)

ALTERRA Post-Approval Study

Barber and Pharmacist Coordination to Improve Blood Pressure Management

A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy

Safety and Effectiveness of Left Bundle Branch Area Pacing Versus Conventional Cardiac Resynchronization Therapy in Heart Failure

Direct Comparison of Cardiac CT With TEE to Evaluate Watchman FLX LAA Occluder Device Characteristics

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

About this Cedars-Sinai Medical Center institution page